The $23 Optimism and the $15 Doubt: UiPath’s AI Bet Has Two Price Tags

(SeaPRwire) –   By: Oliver Hawthorne

UiPath’s stock dropped 16 percent in a single week. That was its worst drop in over four months. The market wasn’t reacting to bad news exactly. It was reacting to a question nobody could answer yet. Would AI actually accelerate deployment speed or just add overhead? Wall Street responded the way Wall Street always does. They raised price targets while keeping ratings flat or worse. Citi broke ranks. Yitchuin Wang initiated coverage with a Buy rating and a $23 price target. He argued the selloff opened a genuine buying window. His reasoning centered on one idea. Enterprise AI will require orchestration across agents, models, humans, APIs, and robots. Automation stays critical for governance and compliance. That’s a structural argument, not a timing argument. Wang believes the post-earnings selloff created an attractive entry point. The rest of the sell side agreed revenue was solid. Nobody could confirm AI was driving faster growth yet. Koji Ikeda at Bank of America raised his target to $15 from $13. He kept an Underperform rating. His reasoning was direct. The earnings report didn’t prove AI would speed up annual recurring revenue growth. BofA did adjust its model to reflect stronger margin expectations. That adjustment is telling. They’re modeling for improved margins but still not betting on the growth story. Truist lifted its target to $17 from $12. Hold rating. The firm sees more agentic AI deals and some improvement in customer growth. But it said it needs to see faster growth before turning more positive. TD Cowen raised from $13 to $16. Hold. It flagged steady Q2 performance, stable customer retention, and growing AI use as positives. DA Davidson’s Lucky Schreiner moved from $12 to $16. Neutral. He noted UiPath beat ARR expectations. The company modestly lifted its fiscal 2027 ARR outlook. Four firms raised targets. Four firms held or downgraded conviction. The technology thesis is winning. The financial thesis is not. Zacks gave UiPath a D on its Value Style Score. The stock trades at a premium to peers. Growth acceleration is too modest to justify the valuation gap. The core contradiction sits here. The AI automation narrative gets louder every quarter. The financial proof stays silent. Enterprise buyers keep asking the same question. If agentic AI orchestrates workflows across agents, models, humans, APIs, and robots, why hasn’t that translated into faster ARR? Wang’s answer is that orchestration is the moat. Automation will remain critical for governance and compliance as AI scales. That’s defensible. But it’s a slower growth story. Governance moves at regulatory pace. Not product launch pace. Six of the major rating actions were target upgrades with held or downgraded conviction. That’s the market telling investors the thesis is real but the timeline is wrong.

The numbers paint a picture of incremental progress. Fiscal Q2 revenue hit $410.26 million. Up 13 percent year over year. Beat the analyst consensus of $397.8 million. Adjusted EPS came in at $0.15. Right in line with expectations. Gross margin slipped to 80 percent from 82 percent a year ago. Two percentage points down. Not alarming on its own. Directionally wrong for a company selling AI-powered automation though. The margin compression likely reflects rising AI infrastructure costs. When you burn more compute on AI inference, gross margin takes a hit. That’s a structural cost, not a temporary one. Wall Street expected $0.19 per share for the current quarter. Up 18.8 percent year over year. Current fiscal year consensus is $0.80 per share. Up 11.1 percent. Revenue estimates for the current quarter stand at $444.34 million. That points to 8.1 percent growth year over year. Q3 growth is lower than Q2’s 13 percent. That deceleration rattled investors. The growth rate is compressing just as the AI story demands acceleration. UiPath’s investor day is set for September 22. Management will lay out plans to drive higher growth. The question is what those plans look like. Will they include specific ARR growth commitments or more strategic positioning language? Truist noted more agentic AI deals and some customer growth improvement. The firm said it needs faster growth before turning positive. TD Cowen flagged steady Q2 performance. Stable customer retention. Growing AI use. These are steady but not explosive. DA Davidson noted UiPath beat ARR expectations. The company modestly lifted its fiscal 2027 ARR outlook. Those are incremental wins. Incremental wins don’t re-rate a stock from Underperform to Buy. Zacks rates PATH a #2 (Buy), pointing to steady earnings estimate trends despite the valuation premium. The stock edged 0.2 percent higher in Tuesday’s premarket on Citi’s note. That barely registers against a 16 percent weekly drop. The market is waiting for something bigger than a single Buy rating from one firm.

The commercial loop UiPath needs to close is clear. Enterprise AI adoption requires orchestration layers. Those layers connect autonomous agents with existing business processes. UiPath’s installed base of robot execution environments gives it distribution advantage. The challenge is pricing that orchestration without cannibalizing RPA revenue. Customers won’t pay twice. Once for RPA licenses and again for AI orchestration. Bundling is the likely path forward. Revenue per customer might grow. New customer acquisition could slow. Gross margin could compress further as AI inference costs get passed down. Citi’s Wang sees the orchestration layer as a governance necessity. That’s a defensible position. It’s also a slower growth thesis. Governance and compliance move at regulatory pace. Not product launch pace. The sell-side consensus reflects that split. Four firms raised targets. Four firms held ratings. Price targets range from $15 to $23. That’s 8 percent to 44 percent implied upside depending on the analyst. No one gave it a Strong Buy. The market is telling investors the AI automation thesis is real. The financial timeline is longer than expected. The September 22 investor day is the next checkpoint. If management walks in with specific ARR growth commitments tied to AI deployments, the $23 target could become consensus. If they walk in with strategic vision and less unit economics, the $15 target becomes the ceiling. Until then, the 16 percent selloff is less a panic event and more a repricing to reality. The automation market will keep growing. The question is whether UiPath grows with it or gets squeezed between hyperscaler AI platforms and point-solution startups. That squeeze is the real risk. No analyst has priced it in yet.

Author bio: Oliver Hawthorne, a Principal Correspondent for an international technology review, covers enterprise AI infrastructure, automation markets, and the intersection of capital allocation with technological infrastructure spending.